Sign In
Buy NVTA
$0.0190
+0 (+0%)
At Close: May 13, 2024
We're really excited that these genomics companies, says Ark's Simon Barnett
07:02pm, Monday, 12'th Apr 2021
Simon Barnett, ARK Invest's genomics analyst, discusses the company's belief in Invitae, its other top picks and why ARK invests the way it does.
3 Top Healthcare Stocks to Buy in April
06:40am, Saturday, 10'th Apr 2021
All three companies have enjoyed major growth catalysts since the start of 2021.
Invitae Stock Price: $48 Target By Oppenheimer
06:47pm, Friday, 09'th Apr 2021
The shares of Invitae (NYSE: NVTA) have received a price target of $48 by Oppenheimer. These are the details.
SAN FRANCISCO, April 8, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, has joined eMERGE Network, a nationwide effort organized and funded by the National H
Invitae to receive £830 million from SoftBank-led group of investors
10:57am, Monday, 05'th Apr 2021
In an announcement on Monday, Invitae Corp (NYSE: NVTA) said it will receive £830 million investment from several investors, including the Japanese multinational conglomerate holding company, SoftBan
Invitae Stock Price Increased Over 10% Pre-Market: Why It Happened
08:42am, Monday, 05'th Apr 2021
The stock price of Invitae Corp (NYSE: NVTA) has increased by over 10% pre-market. This is why it happened.
Invitae to acquire Genosity to accelerate access to personalized oncology testing worldwide
07:30am, Monday, 05'th Apr 2021
SAN FRANCISCO, April 5, 2021 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Genosity Inc. ("Genosity")
ARK Genomic Revolution Multi-Sector ETF: Poised For Continued Underperformance
07:27am, Friday, 02'nd Apr 2021
ARK Genomic Revolution Multi-Sector ETF: Poised For Continued Underperformance
Eli Casdin on looking for opportunity in life sciences
01:42pm, Thursday, 01'st Apr 2021
Eli Casdin, Casdin Capital founder and CIO, on the top life sciences opportunities he sees in the markets, and how he decides which companies are good investments.
Invitae introduces new program to increase access to genetic testing for adult neurodegenerative conditions
07:30am, Thursday, 01'st Apr 2021
SAN FRANCISCO, April 1, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced the availability of sponsored genetic testing for patients in the U.
3 Top Artificial Intelligence Stocks to Buy in April
07:45am, Wednesday, 31'st Mar 2021
AI applications will only increase as the world gets more efficient and these companies hope to take advantage.
Invitae (NVTA) Stock Sinks As Market Gains: What You Should Know
06:58pm, Friday, 26'th Mar 2021
Invitae (NVTA) closed the most recent trading day at $34.45, moving -0.61% from the previous trading session.
Why Invitae Stock Tumbled Today
03:29pm, Wednesday, 24'th Mar 2021
Blame a broader market sell-off of growth stocks.
Is This Underappreciated Cathie Wood Stock a Better Buy Than Tesla Right Now?
06:01am, Friday, 19'th Mar 2021
It definitely could have more upside potential.
How Do Fulgent Genetics and Invitae Stack Up Against Each Other?
07:01am, Saturday, 13'th Mar 2021
These two genetic testing companies have different approaches.
